SCHEMBL20964673

SCHEMBL20964673

Cc1ccc(Cl)cc1N1CCN(C(=O)c2cccnc2SCc2c(C)noc2C)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.58
MEN1 O00255 1/20 0.58
NPC1 O15118 1/20 0.58
KMT2A Q03164 1/20 0.58
LMNA P02545 5/20 0.54
SMN1; SMN2 Q16637 3/20 0.54
TSHR P16473 2/20 0.54
ALDH1A1 P00352 2/20 0.54
AR P10275 5/20 0.51
RAB9A P51151 1/20 0.49
PAX8 Q06710 1/20 0.49
HTT P42858 3/20 0.49
GAA P10253 2/20 0.49
NPSR1 Q6W5P4 2/20 0.49
USP2 O75604 1/20 0.49
MAPK1 P28482 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20964627 0.88 LMNA (0.62) MAPTMEN1NPC1KMT2ALMNA
SCHEMBL20965350 0.87 SMN1; SMN2 (0.49) MAPTMEN1NPC1KMT2ALMNA
SCHEMBL20964621 0.86 SMN1; SMN2 (0.54) MAPTLMNASMN1; SMN2TSHRALDH1A1
SCHEMBL20964609 0.83 ALDH1A1 (0.61) MAPTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL20964600 0.82 TSHR (0.56) MAPTMEN1KMT2ALMNASMN1; SMN2
SCHEMBL20964660 0.82 SMN1; SMN2 (0.63) MAPTNPC1LMNASMN1; SMN2TSHR
SCHEMBL19744985 0.81 SMN1; SMN2 (0.62) MAPTNPC1LMNASMN1; SMN2TSHR
SCHEMBL20964632 0.81 SMN1; SMN2 (0.57) MAPTNPC1KMT2ALMNASMN1; SMN2
SCHEMBL20964554 0.81 SMN1; SMN2 (0.54) MAPTNPC1LMNASMN1; SMN2TSHR
SCHEMBL20964706 0.80 SMN1; SMN2 (0.56) MAPTMEN1NPC1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10851096-B2 Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2020-12-01 US disclosed
US-20190127361-A1 Therapeutic Compounds RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2019-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190127361-A1 Therapeutic Compounds SDHA, SLC10A1, SERPINC1 MAPT 1626/4885MEN1 179/4885NPC1 11/4885
US-10851096-B2 Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents SERPINC1, F12, RPL35 MAPT 4673/4885MEN1 2387/4885NPC1 2196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.